News

 

At AseBio, we follow the latest news in the biotechnology sector and pass the highlights on to you. You can use the search engine to find news articles we’ve written, contributed by our members or from other stakeholders in the sector. And they are also organised into categories to help you find the topics you’re interested in easily.

Search engine
oryzon
ORYZON reports results and corporate update for Q4 and year ended December 31, 2021
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop…
Partners - Oryzon Genomics
BCN HEALTH
BCN HEALTH strengthens its Health Economics department as a result of Therapeutic Positioning Reports
BCN HEALTH has expanded its Health Economics department following the inclusion of economic…
Partners - BCN Health
Euronext
Euronext launches 7th edition of its pan-European pre-IPO educational programme TechShare
Partners - Euronext
foto 25 enero bcn
BCN HEALTH publishes a study evaluating the incidence, mortality and medical costs associated to melanoma in Spain
El objetivo de este estudio fue analizar las características de los pacientes con melanoma tratados…
Partners - BCN Health
salud mental
54% of Europeans consider their current physical health to be good or very good, as survey reveals public perceptions of health following nearly two years of the Covid 19 pandemic
Coronavirus
“Merck Survey: Europeans' perception of health two years after the start of Covid 19” carried out…
Partners - Merck
mapa ability
Ability Pharmaceuticals continues with the clinical development for ABTL0812 as a first line therapy in advanced pancreatic cancer simultaneously in US, Europe, and Israel
ABTL0812 is administered in combination with FOLFIRINOX in a double blind, randomized and placebo…
Partners - Ability Pharmaceuticals
neurofix
Neurofix opens final funding round before availability of phase IIa results for its clinical trial on its ground-breaking drug
Increase in capital is set to 3.5 million euros with a discount of 10% on a valuation of 20…
Laura Soucek
Peptomyc opens a 25 million round of investment and secures 8.6 million euros from its current partners
The spin-off from VHIO (Vall d'Hebron Institute of Oncology) and ICREA – Peptomyc – has developed…
almirall pic
Almirall initiates experimental phase of Lebrikizumab trial in AD patients that have failed or are unsuitable to oral Cyclosporine
The ADvantage study, whose principal investigator and coordinator is Professor Richard Warren of…
Partners - Almirall